“Taken together, the present data indicate that Halofuginone has a strong potential to contribute to solve keloid disease issues. As an anti-fibrotic molecule, HF was able to regulate the fibrotic response induced by TGF-β1 in keloid fibroblasts by reverting their myofibroblast phenotype from the dark side of the wound healing process. Our study can be considered as a first milestone leading to move Halofuginone forward from bench to bedside as a new tool for keloid disease management.”

Pierre Marty, Brice Chatelain, Thomas Lihoreau, Marion Tissot, Zélie Dirand, Philippe Humbert, Clémence Senez, Eleonora Secomandi, Ciro Isidoro, Gwenaël Rolin, Halofuginone regulates keloid fibroblast fibrotic response to TGF-β induction, Biomedicine & Pharmacotherapy, Volume 135, 2021, 111182, ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2020.111182. (https://www.sciencedirect.com/science/article/pii/S0753332220313755)